285 related articles for article (PubMed ID: 26469118)
1. Detection of Chromosomal Abnormalities with Different In Situ Hybridisation Techniques--the Usefulness in the Qualification of Cancer Patients for Molecularly-Targeted Therapies.
Nicoś M; Wojas-Krawczyk K; Krawczyk P; Milanowski J
Adv Clin Exp Med; 2015; 24(4):715-23. PubMed ID: 26469118
[TBL] [Abstract][Full Text] [Related]
2. Molecular assays in detecting EGFR gene aberrations: an updated HER2-dependent algorithm for interpreting gene signals; a short technical report.
Tsiambas E; Ragos V; Lefas AY; Georgiannos SN; Rigopoulos DN; Georgakopoulos G; Stamatelopoulos A; Grapsa D; Syrigos K
J BUON; 2016; 21(2):512-5. PubMed ID: 27273966
[TBL] [Abstract][Full Text] [Related]
3. Using Somatic Mutations to Guide Treatment Decisions: Context Matters.
Horlings HM; Shah SP; Huntsman DG
JAMA Oncol; 2015 Jun; 1(3):275-6. PubMed ID: 26181166
[No Abstract] [Full Text] [Related]
4. DNA in situ hybridization (interphase cytogenetics) versus comparative genomic hybridization (CGH) in human cancer: detection of numerical and structural chromosome aberrations.
Van Dekken H; Krijtenburg PJ; Alers JC
Acta Histochem; 2000 Feb; 102(1):85-94. PubMed ID: 10726167
[TBL] [Abstract][Full Text] [Related]
5. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract][Full Text] [Related]
6. Lack of access to targeted cancer therapy.
Burki TK
Lancet Oncol; 2015 Oct; 16(13):e482. PubMed ID: 26321211
[No Abstract] [Full Text] [Related]
7. [Diagnosis of aneuploidy with fluorescence in situ hybridization (FISH); value in pregnancies with increased risk for chromosome aberrations].
Ulmer R; Pfeiffer RA; Kollert A; Beinder E
Z Geburtshilfe Neonatol; 2000; 204(1):1-7. PubMed ID: 10721179
[TBL] [Abstract][Full Text] [Related]
8. Common Fluorescence In Situ Hybridization Applications in Cytology.
Savic S; Bubendorf L
Arch Pathol Lab Med; 2016 Dec; 140(12):1323-1330. PubMed ID: 27479335
[TBL] [Abstract][Full Text] [Related]
9. Precision cancer medicine: the future is now, only better.
Tsimberidou AM; Eggermont AM; Schilsky RL
Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
[TBL] [Abstract][Full Text] [Related]
10. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
[TBL] [Abstract][Full Text] [Related]
11. Gene numerical imbalances in cytological specimens based on fluorescence/chromogenic in situ hybridization analysis.
Tsiambas E; Karameris A; Lygeros M; Athanasiou AE; Salemis NS; Gourgiotis S; Ragkos V; Metaxas GE; Vilaras G; Patsouris E
J BUON; 2012; 17(3):593-9. PubMed ID: 23033306
[TBL] [Abstract][Full Text] [Related]
12. Personalising the treatment of prostate cancer.
Gunjur A
Lancet Oncol; 2015 Dec; 16(16):e592. PubMed ID: 26549591
[No Abstract] [Full Text] [Related]
13. What have we learned from exceptional tumour responses?: Review and perspectives.
Mehra N; Lorente D; de Bono JS
Curr Opin Oncol; 2015 May; 27(3):267-75. PubMed ID: 25811347
[TBL] [Abstract][Full Text] [Related]
14. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
Lim SJ; Cantillep A; Carpenter PM
Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
[TBL] [Abstract][Full Text] [Related]
15. Specificity of interphase fluorescence in situ hybridization for detection of chromosome aberrations in tumor pathology.
Tibiletti MG
Cancer Genet Cytogenet; 2004 Dec; 155(2):143-8. PubMed ID: 15571800
[TBL] [Abstract][Full Text] [Related]
16. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
Blumenthal GM; Mansfield E; Pazdur R
JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
[No Abstract] [Full Text] [Related]
17. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
[TBL] [Abstract][Full Text] [Related]
18. Maurie Markman on the Groundbreaking TAPUR Trial.
Markman M
Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751
[No Abstract] [Full Text] [Related]
19. Personalized Medicine: Genomics Trials in Oncology.
Hayes DF; Schott AF
Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
[TBL] [Abstract][Full Text] [Related]
20. Anticipating designer drug-resistant cancer cells.
Frangione ML; Lockhart JH; Morton DT; Pava LM; Blanck G
Drug Discov Today; 2015 Jul; 20(7):790-3. PubMed ID: 25697478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
